Black Book Research acknowledges the top-performing hospital technology companies within various clinical market segments based on the industry's largest client survey of inpatient providers at the Healthcare Information Management Systems Society annual conference in Chicago this week.

CHICAGO, April 17, 2023 (Newswire.com) - Black Book Research, the premier source of unbiased, crowdsourced, competitive intelligence, and buyer opinion mining serving the technology and managed services sectors, announces the first round of 2023 awards for highest hospital user experience and clinician satisfaction. Black Book survey results released today include EHR, Population Health, Clinical Department Support, Nursing, Patient Engagement, and Interoperability. The 2023 Black Book awards for Revenue Cycle Management, Finance, Analytics, Cybersecurity, and AI categories will be announced in May.

"Black Book is committed to innovative research, customer satisfaction, loyalty polling, and analysis of the strategic buyer issues in the healthcare marketplace free from the influence of vendors," said Doug Brown, President of the firm. "It is an exciting time at Black Book, as our team is introducing unrivaled user experience surveying tools, the industry's most robust client satisfaction database, innovative reporting functionalities, and a knowledge management system that enables customers to share relevant, informed feedback in real-time." 

Black Book, its founders, owners nor its employees hold any financial interest in the companies contained in any comparison performance report and is not incentivized to recommend any of the ten thousand healthcare industry products and services vendors collected for the last decade. 

The highest-scoring hospital IT and support suppliers in the past year's Black Book client experience polls with HIMSS23 trade show presence are recognized with their exhibit hall booth number:

1UPHEALTH (4357)

ACCENTURE (1725)

AGFA (1902)

ALTERA DIGITAL HEALTH (4053)

AMAZON WEB SERVICES (2056)

AMWELL (3306)

ANDOR HEALTH (2875)

ARCADIA.IO (152)

AT&T  (931)

ATHENAHEALTH (2031)

BAKER TILLY (452)

BAMBOO HEALTH (7943)

BAXTER HEALTHCARE (4071)

BD (1248)

BEST BUY HEALTH (7506)

BIOFOURMIS (7319)

CAPSA HEALTHCARE (2844)

CARE.AI (3431)

CAREGILITY  (6815)

CDW HEALTHCARE (1263)

CENTRAK (134)

CHIPSOFT (3316)

CITIUSTECH (2812)

CROWDSTRIKE (4327)

DELOITTE (1209)

ENLITIC (7316)

EPIC SYSTEMS (956)

EVRY USA TIETOEVRY (6025)

FINTHRIVE (3670)

FORTINET (873)

HURON (1931)

HYLAND (1255)

IBM (2681)

IMPRIVATA (1841)

INFOR (967)

INNOVACCER (2216)

INTELICHART (3406)

INTERFACEWARE (3474)

INTERSYSTEMS (942)

IQVIA (8221)

LEIDOS (1221)

LIGHTBEAM HEALTH SOLUTIONS (3401)

LINUS HEALTH (438)

MDCLONE (4303)

MICROSOFT CLOUD (1201)

NETSMART (7946-53)

NEXTGEN HEALTHCARE (7946-66)

NUANCE (912)

OPTUM (1231)

ORACLE HEALTH   (921)

PHILIPS (901)

PHREESIA (8300-25)

PROOFPOINT (145)

PWC (3434)

RAD AI (7119)

REDOX (2638)

REVSPRING (2248)

SALESFORCE (2606)

SCC SOFT (1736)

SNOWFLAKE (8115)

SPOK  (2586)

SYMPLR (1867)

TEGRIA (1481)

THE SSI GROUP (319)

TYTOCARE   (3809)

UIPATH (7140)

VERADIGM  (3681)

VERIZON (4048)

WAYSTAR (2267)

WOLTERS KLUWER (431)

XIFIN (3631)

For a full list of Black Book's top-ranked hospital category leaders (EHR, Population Health, Clinical Department Support, Nursing, and AI), visit http://www.blackbookmarketresearch.com

About Black Book™
Black Book Market Research LLC, provides healthcare decision makers, IT users, media, investors, analysts, quality-minded vendors, prospective software system buyers, pharmaceutical manufacturers, and other interested sectors of the clinical technology industry with comprehensive comparison data of the industry's top respected and competitively performing technology and managed services vendors in the sector.

The largest user opinion poll of its kind in healthcare IT, the Black Book™ database of user satisfaction houses over 2,000,000 viewpoints on information technology, capital equipment, emerging technology, consulting firms, and outsourced services vendor performance with thousands of updates added every week throughout the year. For methodology, auditing, resources, comprehensive research, and ranking data, see http://www.blackbookmarketresearch.com

Contact Information:
Press Office
[email protected]
8008637590




Original Source: The 70 Top Client-Rated Hospital Technologies Exhibiting at HIMSS23, Black Book Clinical User Survey Results

SAN DIEGO, April 17, 2023 (Newswire.com) - Genome Insight, a leading precision medicine and genomics company, announced that their innovative whole genome sequencing (WGS) approach will be featured in six poster presentations at the American Association of Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL. These posters cover a range of topics, including a study of integrative biomarker analysis of regorafenib plus nivolumab (RegoNivo) in hepatocellular carcinoma (HCC), as well as a comparison between whole-genome sequencing-based and targeted panel sequencing approaches to precision oncology.

One notable presentation highlights that Genome Insight's WGS approach provides a more thorough analysis of genetic mutations in breast cancers with homologous recombination deficiency (HRD) than traditional BRCA gene testing. WGS can accurately classify HR status and identify which patients would benefit from polymerase enzymes (PARP) inhibitor treatment, making it a fast and effective screening tool.

"We are thrilled to present our WGS approach at the AACR annual meeting, which demonstrates the potential of our innovative approach to impact clinical decision-making for patients with cancer." - Dr. Young Seok Ju, CEO of Genome Insight

For more information about Genome Insight's WGS approach and other services, visit www.genomeinsight.net.

About Genome Insight 

Genome Insight is a precision medicine whole genome platform company with the goal to accelerate the use of whole genome sequencing (WGS) for accurate diagnosis and personalized treatment for cancer and rare diseases. Genome Insight's proprietary platform is an automated WGS pipeline coupled with a bioinformatics-powered digital solution that rapidly generates meaningful medical insights, making it possible to use WGS in real-life clinical settings. Furthermore, this platform is applied in the research setting to advance novel therapeutic strategies in cancer and rare diseases. The company's headquarters is in San Diego (US) with offices in Korea (Seoul and Daejeon) and Hong Kong. To learn more, please visit www.genomeinsight.net

Contact Information:
Steven Esparza
Chief Executive Officer
[email protected]
6193631368


Original Source: Genome Insight's Innovative Whole Genome Sequencing Approach to Be Showcased at AACR (American Association of Cancer Research) Annual Meeting 2023

The $50,000 Vilcek Prizes for Creative Promise recognize rising immigrant scientists living and working in the United States whose work represents a significant contribution to their field.

NEW YORK, April 17, 2023 (Newswire.com) - Edward Chouchani receives a Vilcek Prize for Creative Promise in Biomedical Science for his work to decipher the molecular mechanisms that drive metabolic disease, with the aim of developing therapeutic interventions. 

The Vilcek Prize for Creative Promise is a $50,000 recognition awarded annually by the Vilcek Foundation as part of its prizes program. Awarded annually since 2006, the Vilcek Foundation prizes recognize and celebrate immigrant contributions to scientific research and discovery, and to artistic and cultural advancement in the United States. The Vilcek Foundation prizes support the Vilcek Foundation's mission to raise public awareness of the value of immigration for a robust society. 

As part of the Vilcek Foundation's recognition of Chouchani's work, the foundation has produced a biographical profile and video profile celebrating his experience and research. Titled "Edward Chouchani seeks to understand the role of metabolism in disease," it is now available on the Vilcek Foundation website.

Born in Canada to an Egyptian academic, Chouchani grew up attending schools in Greece, Thailand, and Cuba as his father's work took the family abroad. This peripatetic lifestyle and a fascination with science fiction literature fostered an innate curiosity in Chouchani about human life and biology. He earned a BS in biochemistry and biotechnology at Carleton University in Ottawa, and his Ph.D. in biological sciences at the University of Cambridge. In 2014, he moved to Boston to pursue postdoctoral research at Harvard Medical School, where he is now an associate professor of cell biology. Chouchani directs a research laboratory at the Dana-Farber Cancer Institute, where he is also an associate professor of cancer biology. 

"Edward Chouchani's research has had a powerful impact on our current understanding of metabolism and mitochondrial biology," says Vilcek Foundation Chairman and CEO Jan Vilcek. "His approach encompasses the spectrum of research, from bench science to computational analysis. With this approach, he has not only developed new tools and methods to study metabolism in cells, but has identified potential clinical applications and interventions for metabolic and metastatic disorders and disease."

Chouchani's work primarily focuses on metabolism, using mass spectrometry and biochemical approaches to understand how metabolites regulate cellular function in pre-clinical models of health and disease. The research implications are myriad: By better understanding the function of metabolism and the role that different metabolites play in living cells and tissues, Chouchani and his team can identify metabolites and enzymes that contribute to disease.

"Mass spectrometry lets us peer into the cell and systematically map how metabolism controls our biology," he says. "Our goal is to leverage these newfound mechanisms to develop new therapies for metabolic, inflammatory, and metastatic diseases."

"There are over 20,000 different types of protein machines in the cell and over 95% of them are what's called un-drugged," he says. "The way our technology works, we query many of those 20,000 proteins in living systems and look for pockets where small-molecule metabolites can interact with them." By finding and understanding these pockets, Chouchani and his team illuminate metabolic functions and identify potential points of intervention. "If we can understand the nooks and crannies of where these interactions occur, we can develop new ways to leverage these interactions, and protect against cancers and diseases of aging."

Chouchani is energized by his work, and takes inspiration from his research team and colleagues at Harvard. "That really is one of the most invigorating things about science," he says. "If you're doing it properly, and with the right people, it starts evolving in ways you never could have anticipated, and it makes it one of the most exciting careers that one can have."

Access the full article and video at the Vilcek Foundation: Edward Chouchani seeks to understand the role of metabolism in disease

Contact Information:
Elizabeth Boylan
Communications Manager
[email protected]
+12124722500
Related Files
2023VFP - Press Release - Edward Chouchani - Newswire.pdf



Original Source: Vilcek Foundation Awards $50,000 Prize to Immigrant Biochemist Edward Chouchani

The SYNGAP1 Gene: Seeking Treatments and the Genetic Link to Related Neurological Disorders

WASHINGTON, April 17, 2023 (Newswire.com) - The SYNGAP1 Foundation has released its SYNGAP1: Voice of the Patient and Caregiver Report, a landmark publication based on its Nov. 19, 2020, externally led patient-focused drug development (EL-PFDD) meeting. Families and caregivers living with SYNGAP1 participated via Zoom, email, and calling in, sharing stories and input captured in the Voice of the Patient Report. It will provide the FDA and the biopharmaceutical industry with deep insights into how SYNGAP1-related disorders affect individuals' health, daily lives, and well-being. Individuals and families living with SYNGAP1-related conditions shared with U.S. Food and Drug Administration (FDA) representatives and other stakeholders about how the neurodevelopmental disorder affects symptoms and hopes for future treatments to improve quality of life. 

The SYNGAP1 gene provides instructions for making a protein called SynGAP, which plays an essential role in nerve cells in the brain. SYNGAP1 mutations' prevalence is 2%-4% of sporadic (non-Inherited) cases of intellectual disability worldwide. Five out of 500 persons diagnosed with epileptic encephalopathy have a SYNGAP1 mutation. The frequency of these mutations is like that of Fragile X Syndrome, the most common inherited cause of Intellectual Disability ("ID worldwide"). Gene Reviews 

The report describes the array of clinical symptoms suffered by individuals with SYNGAP1 mutations, a few being the most common, such as developmental delay, intellectual disability, epilepsies, speech delay, impaired communication, and sensory processing disorder. One individual explained a few of her symptoms living with SYNGAP1, "I'm obsessed with making lists and organizing, and I have sensory issues related to noise and certain textures." Another mother described her concern for her toddler: "He didn't take his first steps until he was almost two, and shortly before his second birthday, he began walking independently. His gross motor skills were delayed, and he had trouble doing simple tasks, such as feeding himself." The average age for walking is 26 months (range: 10.5 months to 5 years). Language is generally impaired; a third of individuals aged five years or more remain nonverbal. In those who are verbal, language development ranges from the use of single words only to four-to-five-word sentences. 

In addition, other symptoms observed in patients include inattention, impulsivity, self-directed and other-directed aggressive behavior, elevated pain threshold, hyperacusis, and sleep disorders, which also include autism spectrum disorders (ASD). Autism diagnosis may be as high as 50% of SYNGAP1 patients, including stereotypic behaviors such as hand flapping, obsessions with objects, and poor social development. 

Short of a cure, families consistently stated that the top three symptoms as the target of a new therapy would be the ability to control seizures, improved behavioral control, and improved ability to communicate. Many people also indicated help with motor skills and self-care, halting disease progression, improved social interactions, and improved cognitive ability. Being understood is a top desire of caregivers and families. The common theme in comments shared during the meeting is that families and caregivers living with SYNGAP1-related disorders are willing to tolerate a higher degree of uncertainty about the effectiveness of a new drug, given the dire, unmet need they currently experience. A mother of a child expressed, "I hope that something comes out to target the root of the problem, which will alleviate many of the symptoms. We desperately need something, because the side effects often outweigh the benefits of many meds." Another testified, "Since this is so incapacitating, even invasive therapy delivery procedures will be welcome."

Contact Information:
Monica Dudley-Weldon
President & Founder, SYNGAP1 Foundation
[email protected]
2403470302

Matt Toresco
Chief Operations Officer/ SYNGAP1 Foundation
[email protected]


Original Source: Landmark Report Captures Compelling Testimony by Families and Caregivers About Living with SYNGAP1-related Disorders and Urgent Need for Treatments